Cancer Research Unit, Department of Biology, University of York, Heslington, UK.
Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK.
FEBS Open Bio. 2022 Jul;12(7):1365-1387. doi: 10.1002/2211-5463.13417. Epub 2022 May 6.
This study aimed to elucidate the role of ELF3, an ETS family member in normal prostate growth and prostate cancer. Silencing ELF3 in both benign prostate (BPH-1) and prostate cancer (PC3) cell lines resulted in decreased colony-forming ability, inhibition of cell migration and reduced cell viability due to cell cycle arrest, establishing ELF3 as a cell cycle regulator. Increased ELF3 expression in more advanced prostate tumours was shown by immunostaining of tissue microarrays and from analysis of gene expression and genetic alteration studies. This study indicates that ELF3 functions not only as a part of normal prostate epithelial growth but also as a potential oncogene in advanced prostate cancers.
本研究旨在阐明 ELF3(ETS 家族成员之一)在正常前列腺生长和前列腺癌中的作用。沉默良性前列腺(BPH-1)和前列腺癌细胞系(PC3)中的 ELF3 会导致集落形成能力下降、细胞迁移抑制以及细胞活力因细胞周期停滞而降低,从而确立 ELF3 作为细胞周期调节剂的作用。通过组织微阵列的免疫染色以及基因表达和遗传改变研究的分析,显示在更晚期的前列腺肿瘤中 ELF3 表达增加。这项研究表明,ELF3 不仅作为正常前列腺上皮生长的一部分发挥作用,而且在晚期前列腺癌中作为潜在的致癌基因发挥作用。